Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry
In our monthly newsletter, we share the latest news from Veratrak & industry insights from the Pharma supply chain. To receive it straight to your inbox,?subscribe to the email version.
In an era of increasing environmental consciousness, the pharmaceutical industry finds itself at a critical juncture. With the implementation of the EU's Corporate Sustainability Reporting Directive in January 2024, large pharmaceutical organisations are facing growing pressure to enhance their sustainability reporting practices.
Our latest white paper, "Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry," offers an in-depth exploration of this timely topic.
The paper discusses the growing emphasis on addressing Scope 3 emissions and the trend towards more comprehensive reporting and adoption of science-based targets.
?Here's a glimpse of what you'll discover in our comprehensive analysis:
领英推荐
?? This white paper is an essential resource for pharmaceutical industry professionals, sustainability experts, and anyone interested in the intersection of healthcare and environmental responsibility.
Download now to gain valuable insights into the current state of Scope 3 emissions reporting in the pharma industry and the path forward towards a more sustainable future.
?? Meet with us at Logipharma in Boston, USA, where Jason Lacombe, CEO at Veratrak, will take the stage to participate in the panel discussion: “Leveraging Your Partnerships to Reduce Scope 3 Emissions”, and share his knowledge and insights on the latest trends, challenges, and best practices in pharma supply chain management.
We invite you also to visit our booth #148 to discover how digital technology enablers like Veratrak are helping to integrate data from disparate sources, streamline supply chains, and support standardised Scope 3 emissions reporting.